World's Best Scientists 2026 revealed!
Ruben Smith

Ruben Smith

D-Index & Metrics

Neuroscience

D-Index
57
Citations
14689
World Ranking
4296
National Ranking
78

Overview

Ruben Smith is affiliated with Lund University in Sweden and focuses extensively on research in the field of medicine, with particular emphasis on physiology, psychiatry and mental health, radiology, nuclear medicine and imaging, cognitive neuroscience, and neurology. Their work primarily addresses several key topics including Alzheimer's disease research and treatments, dementia and cognitive impairment research, functional brain connectivity studies, advanced neuroimaging techniques and applications, medical imaging techniques and applications, neurological disease mechanisms and treatments, and Parkinson's disease mechanisms and treatments.

Recent papers by Ruben Smith illustrate a concentration on biomarkers and pathological mechanisms related to Alzheimer's disease. These include:

  • Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders, 2020, published in JAMA
  • Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia, 2020, published in Nature Medicine
  • Four distinct trajectories of tau deposition identified in Alzheimer's disease, 2021, published in Nature Medicine
  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease, 2020, published in Nature Communications
  • Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease, 2021, published in Brain

Ruben Smith frequently collaborates with a set of co-authors who contribute prominently to their research output. These collaborators include:

  • Oskar Hansson
  • Olof Strandberg
  • Erik Stomrud
  • Rik Ossenkoppele
  • Sebastian Palmqvist

Smith's research findings are regularly published in a range of scientific journals and venues. Frequent publication outlets include:

  • Alzheimer s & Dementia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • JAMA Neurology
  • Brain
  • Nature Communications

Their body of work comprises over 340 publications in the broader field of medicine, with significant contributions to subfields such as physiology and psychiatry, reflecting a multidisciplinary engagement with neurological and cognitive disorders. The scope of topics covered illustrates an integration of clinical biomarker research, neuroimaging, and neuropathological studies, focused on improving the understanding of disease mechanisms and progression in Alzheimer's disease and related neurodegenerative conditions.

Best Publications

  • Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

    Sebastian Palmqvist;Shorena Janelidze;Yakeel T. Quiroz;Yakeel T. Quiroz;Henrik Zetterberg

  • Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

    Shorena Janelidze;Niklas Mattsson;Sebastian Palmqvist;Ruben Smith

  • Four distinct trajectories of tau deposition identified in Alzheimer’s disease

    Jacob W Vogel;Alexandra L Young;Neil P Oxtoby;Ruben Smith

  • Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

    Unknown

  • Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.

    Joana B Pereira;Joana B Pereira;Shorena Janelidze;Ruben Smith;Niklas Mattsson-Carlgren

  • Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    Jacob W. Vogel;Yasser Iturria-Medina;Olof T. Strandberg;Ruben Smith

  • Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders

    Rik Ossenkoppele;Rik Ossenkoppele;Gil D. Rabinovici;Ruben Smith;Hanna Cho

  • Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.

    Shorena Janelidze;Erik Stomrud;Ruben Smith;Sebastian Palmqvist

  • Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

    Unknown

  • Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

    Shorena Janelidze;David Berron;Ruben Smith;Olof Strandberg

  • Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease.

    Niklas Mattsson-Carlgren;Emelie Andersson;Shorena Janelidze;Rik Ossenkoppele;Rik Ossenkoppele

  • Orexin loss in Huntington's disease

    Åsa Petersén;Joana Gil;Marion L.C. Maat-Schieman;Maria Björkqvist

  • Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.

    Rik Ossenkoppele;Ruben Smith;Tomas Ohlsson;Olof Strandberg

  • Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

    Rik Ossenkoppele;Rik Ossenkoppele;Ruben Smith;Niklas Mattsson-Carlgren;Colin Groot

  • Synaptic dysfunction in Huntington's disease: a new perspective

    Ruben Smith;Patrik Brundin;Jia-Yi Li

  • Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

    Niklas Mattsson-Carlgren;Shorena Janelidze;Randall J Bateman;Ruben Smith

  • Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.

    Antoine Leuzy;Ruben Smith;Rik Ossenkoppele;Rik Ossenkoppele;Alexander Santillo

  • Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease

    Joana B Pereira;Joana B Pereira;Shorena Janelidze;Rik Ossenkoppele;Rik Ossenkoppele;Hlin Kvartsberg;Hlin Kvartsberg

  • Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

    David Berron;Jacob W Vogel;Philip S Insel;Philip S Insel;Joana B Pereira

  • 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

    Ruben Smith;Andreas Puschmann;Michael Schöll;Michael Schöll;Tomas Ohlsson

  • 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

    Niklas Mattsson;Michael Schöll;Olof Strandberg;Ruben Smith

  • Increased metabolism in the R6/2 mouse model of Huntington's disease.

    Jorien M.M. van der Burg;Karl Bacos;Nigel I. Wood;Andreas Lindqvist

  • Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.

    Michael Schöll;Michael Schöll;Rik Ossenkoppele;Olof Strandberg;Sebastian Palmqvist

  • Cholinergic neuronal defect without cell loss in Huntington's disease.

    Ruben Smith;Hinfan Chung;Sara Rundquist;Marion L.C. Maat-Schieman

Frequent Co-Authors

Rik Ossenkoppele
Rik Ossenkoppele Lund University
Sebastian Palmqvist
Sebastian Palmqvist Lund University
Erik Stomrud
Erik Stomrud Lund University
Michael Schöll
Michael Schöll University of Gothenburg
Shorena Janelidze
Shorena Janelidze Lund University
Kaj Blennow
Kaj Blennow University of Gothenburg
Philip S. Insel
Philip S. Insel University of California, San Francisco
Henrik Zetterberg
Henrik Zetterberg University of Gothenburg
Renaud La Joie
Renaud La Joie University of California, San Francisco
Joana B. Pereira
Joana B. Pereira Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Ruben Smith

Trending Scientists

Recently Published Articles